Why Amdocs Limited (NASDAQ:DOX) Could Be A Buy

Amdocs Limited (NASDAQ:DOX), a it company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $70.3 and falling to the lows of $63.79. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether Amdocs's current trading price of $66.28 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Amdocs’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Check out our latest analysis for Amdocs

Is Amdocs still cheap?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 2.76% below my intrinsic value, which means if you buy Amdocs today, you’d be paying a fair price for it. And if you believe the company’s true value is $68.16, then there isn’t much room for the share price grow beyond what it’s currently trading. Furthermore, it seems like Amdocs’s share price is quite stable, which means there may be less chances to buy low in the future now that it’s fairly valued. This is because the stock is less volatile than the wider market given its low beta.

What does the future of Amdocs look like?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by a double-digit 14.14% over the next couple of years, the outlook is positive for Amdocs. It looks like higher cash flows is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? DOX’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping tabs on DOX, now may not be the most optimal time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Amdocs. You can find everything you need to know about Amdocs in the latest infographic research report. If you are no longer interested in Amdocs, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.